Thursday, February 07, 2008

Multiple Sclerosis Drug May Be Linked to Melanoma

Multiple Sclerosis Drug May Be Linked to Melanoma
HealthDay via Yahoo! News Wed, 06 Feb 2008 2:23 PM PST
WEDNESDAY, Feb. 6 (HealthDay News) -- Almost immediately after a 46-year-old woman with multiple sclerosis received her first dose of the drug Tysabri, a mole that had been on her shoulder for years suddenly took on a dangerous new character.


Diabetes Study Partially Halted After Deaths

Multiple Sclerosis Drug May Be Linked to Melanoma
KOLD News 13 Tuscon Wed, 06 Feb 2008 2:57 PM PST
By Amanda Gardner , HealthDay Reporter WEDNESDAY, Feb. 6 (HealthDay News) -- Almost immediately after a 46-year-old woman with multiple sclerosis received her first...

Multiple Sclerosis Drug May Be Linked to Melanoma
Health Scout Wed, 06 Feb 2008 4:54 PM PST
Doctors report 2 cases of the deadly skin cancer developing in patients taking Tysabri.

Tysabri May Be Linked to Melanoma
WebMD Wed, 06 Feb 2008 2:53 PM PST
Two multiple sclerosis patients developed malignant melanoma -- a deadly form of skin cancer -- soon after starting treatment with Tysabri, researdhers report.

A Ray of Sunshine in the Fight Against Cancer
Newswise Wed, 06 Feb 2008 12:19 PM PST
Dalhousie University epidemiologist Dr. Louise Parker, says a vitamin D pill could block the development of some cancers, strengthen bones, prevent multiple sclerosis and alleviate winter depression.

The Brain Is Harmed By Chronic Pain
People with unrelenting pain don't only suffer from the non-stop sensation of throbbing pain. They also have trouble sleeping, are often depressed, anxious and even have difficulty making simple decisions.

NeuroDigm's Model Reveals The Reversal Of Chronic Pain
Mary Hannaman MD, president of NeuroDigm Co. in Fort Worth, Texas has confirmed that a recombinant human erythropoietin, epoetin alfa, can reverse neural changes that cause chronic pain behavior.

Multiple Sclerosis Drug May Be Linked to Melanoma
U.S. News & World Report - Washington,DC,USA
6 (HealthDay News) -- Almost immediately after a 46-year-old woman with multiple sclerosis received her first dose of the drug Tysabri, a mole that had been ...
See all stories on this topic

Casa Grande Regional Medical Center
Casa Grande Valley Newspapers - Casa Grande,AZ,USA
Primary progressive MS: is characterized by a slow but basically steady decline without distinct periods of relapse and remission. ...
See all stories on this topic

------------------------------------------

Market Update - MS drug Tysabri sales
Sydney Morning Herald - Sydney,New South Wales,Australia
quarter). In addition they reported that the number of patients that were on commercial and clinical which is reflected in the growing sales of the drug. ...
See all stories on this topic

Tysabri May Be Linked to Melanoma
WebMD - USA
6, 2008 -- Two multiple sclerosis patients developed malignant melanoma -- a deadly form of skin cancer -- soon after starting treatment with Tysabri. ...
See all stories on this topic

Biogen Idec chief takes counterjab at Icahn
Boston Globe - United States
"This [Biogen Idec] is one of them" Mullen said Biogen Idec didn't draw any solid offers because of worries about its multiple sclerosis drug, Tysabri, ...
See all stories on this topic

Stocks to Watch - BIIB, NICE, PEX, PTVL
TransWorldNews (press release) - Monroe,GA,USA
Global in-market net sales in 2007 of TYSABRI were $343 million, comprised of $218 million in the US and $125 million in Europe. On a reported basis, ...
See all stories on this topic

Biogen Fourth-Quarter Net Rises 85 Percent on Tysabri (Update2)
Bloomberg - USA
Revenue rose 26 percent from a year earlier to $893 million as worldwide sales of Tysabri quadrupled. Biogen said it expects 100000 patients will be taking ...
See all stories on this topic

Biogen Idec Reports Full Year and Fourth Quarter 2007 Results
FOXBusiness - USA
Global in-market net sales in 2007 of TYSABRI were $343 million, comprised of $218 million in the US and $125 million in Europe. -- On a reported basis, ...
See all stories on this topic

Biogen Idec profit beats expectations
Houston Chronicle - United States
The newer MS treatment Tysabri generated revenue of $90 million, up from $18 million in the year-ago quarter. Tysabri had been seen as a potential ...
See all stories on this topic

Biogen Idec Draws "Line In The Sand" With Carl Icahn
CNBC - Englewood Cliffs,NJ,USA
The company beat the Street, sales of Tysabri for multiple sclerosis were higher than expected and the biotech reaffirmed its 2008 financial guidance. ...
See all stories on this topic

Stocks to Watch - BIIB, NICE, PEX, PTVL
TransWorldNews (press release) - Monroe,GA,USA
Global in-market net sales in 2007 of TYSABRI were $343 million, comprised of $218 million in the US and $125 million in Europe. On a reported basis, ...
See all stories on this topic

Hits and Misses: Wednesday's Earnings Reports
FOXBusiness - USA
A newer MS drug, Tysabri, posted sales of $129 million. The drug was removed from the market in early 2005 due to safety concerns, but reintroduced more ...
See all stories on this topic
------------------------------------------------------------------

Wednesday's Health Winners & Losers
TheStreet.com - USA
Proceeds will go to late-stage development and regulatory filing of Fampridine-SR in multiple sclerosis. Also trailing midweek, Edwards LifesciencesEW said ...
See all stories on this topic

Wednesday's Winners & Losers: Riverbed Technology
TheStreet.com - USA
... and are expected to continue to increase in 2008, primarily due to an increase in spending on the Fampridine-SR clinical and preclinical programs. ...
See all stories on this topic

Acorda Therapeutics To Sell 2.66 Mln Common Shares In Public ...
RTT News - Williamsville,NY,USA
The Company intends to use the net proceeds from this offering to complete its second Phase 3 Fampridine-SR clinical trial in multiple sclerosis and to ...
See all stories on this topic

Acorda Therapeutics, Inc. Announces Proposed Public Offering of ...
FOXBusiness - USA
The Company intends to use the net proceeds from this offering to complete its second Phase 3 Fampridine-SR clinical trial in multiple sclerosis and to ...
See all stories on this topic

Acorda Sinks on Forecast Wider 2008 Loss
Houston Chronicle - United States
... after the biotechnology company said it expects a wider 2008 net loss on higher costs for its experimental multiple sclerosis drug, Fampridine-SR. ...
See all stories on this topic

Acorda Therapeutics To Sell 2.66 Mln Common Shares In Public ...
RTT News - Williamsville,NY,USA
The Company intends to use the net proceeds from this offering to complete its second Phase 3 Fampridine-SR clinical trial in multiple sclerosis and to ...
See all stories on this topic

Acorda proposes sale of 2.75M shares
Business in the Burbs - White Plains,NY,USA
Acorda also plans to use the proceeds from the offering to fund further research into its Fampridine-SR drug for treatment of multiple sclerosis. ...
See all stories on this topic

Lloyd Keir, ‘my hero’ - Wheeler’s tribute to his best mate
Dubbo Daily Liberal - Dubbo,New South Wales,Australia
“He was only about 30 when he contracted multiple sclerosis and it’s been a struggle for him and his family ever since - but the problems he had didn’t ...
See all stories on this topic

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home